The drug acts by inhibiting [[24-dehydrocholesterol reductase]], which catalyzes the final step of cholesterol [[biosynthesis]], the conversion of [[desmosterol]] into cholesterol.<ref name="BurtisAshwood2012">{{cite book|author1=Carl A. Burtis|author2=Edward R. Ashwood|author3=David E. Bruns|title=Tietz Textbook of Clinical Chemistry and Molecular Diagnostics|url=https://books.google.com/books?id=BBLRUI4aHhkC&pg=PA733|date=14 October 2012|publisher=Elsevier Health Sciences|isbn=1-4557-5942-2|pages=733–}}</ref> This results in tissue accumulation of desmosterol, which in turn is responsible for the side effects of triparanol.<ref name="Ravina2011" /> Unlike [[statin]]s, triparanol does not inhibit [[HMG-CoA reductase]], the rate-limiting enzyme in cholesterol biosynthesis,<ref name="Ravina2011" /> and in contrast to triparanol, statins can significantly lower cholesterol levels without resulting in accumulation of intermediates like desmosterol.<ref name="Ravina2011" /> The developmental code name of triparanol, MER/29, became so well-known that it became the registered trade name of the drug.<ref name="Miller1961">{{cite journal|last1=Miller|first1=Lloyd C.|title=Doctors, Drugs, and Names|journal=JAMA|volume=177|issue=1|year=1961|pages=27|issn=0098-7484|doi=10.1001/jama.1961.73040270014004b|quote=Recently, another laboratory code number, MER29, became so well known that it was adopted as the registered trademark for the anticholesterolemic drug concerned (triparanol).}}</ref>

 
[[Estrogen]] is known to lower cholesterol levels, but produces [[side effect]]s like [[gynecomastia]] and decreased [[libido]] in men.<ref name="Li2009">{{cite book|author=Jie Jack Li|title=Triumph of the Heart: The Story of Statins|url=https://books.google.com/books?id=-GPl1PA5EgMC&pg=PA33|date=3 April 2009|publisher=Oxford University Press, USA|isbn=978-0-19-532357-3|pages=33–}}</ref> It was hoped that a drug could be developed that lacked overt estrogenic effects but still lowered cholesterol levels.<ref name="Li2009" /> Triparanol is a [[triphenylethanol]] and was derived from [[chlorotrianisene]] (TACE), a [[nonsteroidal]] [[triphenylethylene]] estrogen,<ref name="Li2009" /><ref name="GrantSchuman1993">{{cite book|author1=W. Morton Grant|author2=Joel S. Schuman|title=TOXICOLOGY OF THE EYE: Effects on the Eyes and Visual System from Chemicals, Drugs, Metals and Minerals, Plants, Toxins and Venoms; also Systemic Side Effects from Eye Medications (4th Ed.)|url=https://books.google.com/books?id=mDLYCQAAQBAJ&pg=PA384|date=1 January 1993|publisher=Charles C Thomas Publisher|isbn=978-0-398-08215-4|pages=384–}}</ref> and the nonsteroidal triphenylethanol [[antiestrogen]] [[ethamoxytriphetol]] (MER-25) is a derivative of triparanol.<ref name="Manni1999">{{cite book|author=Andrea Manni|title=Endocrinology of Breast Cancer|url=https://books.google.com/books?id=7DSYBwAAQBAJ&pg=PA286|date=15 January 1999|publisher=Springer Science & Business Media|isbn=978-1-59259-699-7|pages=286–}}</ref> The [[selective estrogen receptor modulator]] [[clomifene]] is also structurally related to triparanol.<ref name="GrantSchuman1993" /><ref name="Aronson2009">{{cite book|first=Jeffrey K. |last=Aronson |authorlink=Jeffrey Aronson |title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA163|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=163–}}</ref> The developers of triparanol jokingly referred to it as a "non-estrogenic estrogen".<ref name="Li2009" />
